Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2013

01-06-2013 | Preclinical study

Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis

Authors: Julia Hobson, Phani Gummadidala, Brian Silverstrim, Dore Grier, Janice Bunn, Ted James, Mercedes Rincon

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

Development of metastasis in peripheral tissues is a major problem in the fight to cure breast cancer. Although it is becoming evident that chronic inflammation can contribute to tumor progression and metastasis, the effect of acute inflammation in primary tumor is less known. Using mouse models for breast cancer here we show that biopsy of mammary tumors increases the frequency of lung metastases. This effect is associated with the recruitment of inflammatory cells to the lung and elevated levels of certain cytokines such as IL-6 in the lung airways. Antiinflammatory treatment prior to and after the biopsy reduces the development of metastases triggered by the biopsy. In addition, while lack of IL-6 does not affect primary tumor development, it protects from increasing number of metastases upon biopsy. Thus, our studies show that in addition to chronic inflammation, acute immune response caused by invasive procedures in the primary tumor may cause an increased risk on peripheral metastases, but the risk could be decreased by anti-inflammatory treatments.
Literature
1.
go back to reference Grange JM, Stanford JL, Stanford CA (2002) Campbell De Morgan’s observations on cancer, and their relevance today. J R Soc Med 95:296–299PubMedCrossRef Grange JM, Stanford JL, Stanford CA (2002) Campbell De Morgan’s observations on cancer, and their relevance today. J R Soc Med 95:296–299PubMedCrossRef
2.
go back to reference Comen EA (2012) Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med 14:97–104PubMed Comen EA (2012) Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med 14:97–104PubMed
3.
go back to reference Psaila B, Kaplan RN, Port ER, Lyden D (2006) Priming the soil for breast cancer metastasis: the pre-metastatic niche. Breast Dis 26:65–74PubMed Psaila B, Kaplan RN, Port ER, Lyden D (2006) Priming the soil for breast cancer metastasis: the pre-metastatic niche. Breast Dis 26:65–74PubMed
4.
go back to reference Paget S (1889) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98–101 Paget S (1889) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98–101
5.
go back to reference Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101–2114 e2105PubMedCrossRef Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138:2101–2114 e2105PubMedCrossRef
6.
go back to reference Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRef Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRef
7.
go back to reference Roy LD, Ghosh S, Pathangey LB, Tinder TL, Gruber HE, Mukherjee P (2011) Collagen induced arthritis increases secondary metastasis in MMTV–PyV MT mouse model of mammary cancer. BMC Cancer 11:365PubMedCrossRef Roy LD, Ghosh S, Pathangey LB, Tinder TL, Gruber HE, Mukherjee P (2011) Collagen induced arthritis increases secondary metastasis in MMTV–PyV MT mouse model of mammary cancer. BMC Cancer 11:365PubMedCrossRef
8.
go back to reference Roy LD, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P (2009) Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11:R56PubMedCrossRef Roy LD, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P (2009) Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11:R56PubMedCrossRef
9.
go back to reference Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33:119–126PubMedCrossRef Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33:119–126PubMedCrossRef
10.
go back to reference Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27:4709–4717PubMedCrossRef Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27:4709–4717PubMedCrossRef
11.
go back to reference Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J (1998) Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 152:83–92PubMed Bellocq A, Antoine M, Flahault A, Philippe C, Crestani B, Bernaudin JF, Mayaud C, Milleron B, Baud L, Cadranel J (1998) Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 152:83–92PubMed
12.
go back to reference Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224PubMedCrossRef Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19:217–224PubMedCrossRef
13.
go back to reference Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037–1047PubMedCrossRef Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037–1047PubMedCrossRef
14.
go back to reference Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T et al (2011) Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208:479–490PubMedCrossRef Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T et al (2011) Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208:479–490PubMedCrossRef
15.
go back to reference Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302–305PubMedCrossRef Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302–305PubMedCrossRef
16.
go back to reference de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411–423PubMedCrossRef de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411–423PubMedCrossRef
17.
go back to reference Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108:10662–10667PubMedCrossRef Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108:10662–10667PubMedCrossRef
18.
go back to reference Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954–961PubMed
19.
go back to reference Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Constantini F (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189–1196PubMed Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Constantini F (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189–1196PubMed
20.
go back to reference Neveu W, Allard JB, Dienz O, Wargo MJ, Ciliberto G, Whittaker LA, Rincon M (2009) IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol 183:1732–1738PubMedCrossRef Neveu W, Allard JB, Dienz O, Wargo MJ, Ciliberto G, Whittaker LA, Rincon M (2009) IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol 183:1732–1738PubMedCrossRef
21.
go back to reference Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA (2006) Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 177:5186–5194PubMed Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA (2006) Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 177:5186–5194PubMed
22.
go back to reference Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler H, Berry D, Sutton L, Michaelson R, Messino M et al (2006) Interleukin-6 and multidrug resistance protein 1 (PGP-1) expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 100:301–308PubMedCrossRef Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler H, Berry D, Sutton L, Michaelson R, Messino M et al (2006) Interleukin-6 and multidrug resistance protein 1 (PGP-1) expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 100:301–308PubMedCrossRef
23.
go back to reference Baribault H, Wilson-Heiner M, Muller W, Penner J, Bakhiet N (1997) Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. Transgenic Res 6:359–367PubMedCrossRef Baribault H, Wilson-Heiner M, Muller W, Penner J, Bakhiet N (1997) Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. Transgenic Res 6:359–367PubMedCrossRef
24.
go back to reference Waldner MJ, Foersch S, Neurath MF (2012) Interleukin-6–a key regulator of colorectal cancer development. Int J Biol Sci 8:1248–1253PubMedCrossRef Waldner MJ, Foersch S, Neurath MF (2012) Interleukin-6–a key regulator of colorectal cancer development. Int J Biol Sci 8:1248–1253PubMedCrossRef
25.
go back to reference He G, Karin M (2011) NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res 21:159–168PubMedCrossRef He G, Karin M (2011) NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res 21:159–168PubMedCrossRef
26.
go back to reference Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMed Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMed
27.
go back to reference Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10:972–992PubMedCrossRef Shakhar G, Ben-Eliyahu S (2003) Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10:972–992PubMedCrossRef
28.
go back to reference Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–291PubMedCrossRef Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–291PubMedCrossRef
29.
go back to reference Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M (2003) The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res 63:337–341PubMed Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M (2003) The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res 63:337–341PubMed
30.
go back to reference Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M (2003) Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer 88:1084–1090PubMedCrossRef Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M (2003) Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer 88:1084–1090PubMedCrossRef
31.
go back to reference Houghton AM (2010) The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9:1732–1737PubMedCrossRef Houghton AM (2010) The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9:1732–1737PubMedCrossRef
32.
go back to reference Rincon M (2012) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 33:571–577PubMedCrossRef Rincon M (2012) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 33:571–577PubMedCrossRef
33.
go back to reference Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108PubMedCrossRef Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108PubMedCrossRef
34.
go back to reference Sansone P, Bromberg J (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005–1014PubMedCrossRef Sansone P, Bromberg J (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005–1014PubMedCrossRef
35.
go back to reference Rokavec M, Wu W, Luo JL (2012) IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 45:777–789PubMedCrossRef Rokavec M, Wu W, Luo JL (2012) IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 45:777–789PubMedCrossRef
36.
go back to reference Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237–1247PubMedCrossRef Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237–1247PubMedCrossRef
Metadata
Title
Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis
Authors
Julia Hobson
Phani Gummadidala
Brian Silverstrim
Dore Grier
Janice Bunn
Ted James
Mercedes Rincon
Publication date
01-06-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2575-1

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine